Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;30(11):8655-8666.
doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2.

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials

Jessa Gilda P Pandy  1 , Paula Isabel G Franco  2 , Rubi K Li  2
Affiliations
Review

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials

Jessa Gilda P Pandy et al. Support Care Cancer. 2022 Nov.

Abstract

Purpose: Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are common toxicities of several systemic cancer treatments. Multikinase inhibitor-induced HFSR is distinguished from chemotherapy-induced HFS in terms of pathogenesis, symptomatology, and treatment. Multiple trials have investigated the efficacy of preventive strategies such as COX-inhibitors, pyridoxine, and urea cream; however, no consensus has been made. This meta-analysis evaluated data from high-quality trials to provide strong evidence in forming recommendations to prevent systemic cancer therapy-induced HFS/HFSR.

Methods: A systematic search of PubMed, Embase, Cochrane, clinical trials databases, and hand searching were utilized to identify randomized trials (RCTs) investigating prophylactic strategies for HFS/HFSR in cancer patients receiving systemic treatment. Trials published until August 2021 were included. Using the random effects model, pooled odds ratios were calculated for rates of all-grade and severe HFS/HFSR. Subgroup analysis based on type of cancer treatment given was done.

Results: Sixteen RCTs were included (N=2814). For all-grade HFS/HFSR, celecoxib (OR 0.52, 95% CI 0.32-0.85, p=0.009) and urea cream (OR 0.48, 95% CI 0.39-0.60, p<0.00001) both showed statistically significant risk reduction. Celecoxib was effective in preventing HFS in patients who received capecitabine (50.5% vs 65%, p=0.05), while urea cream was effective in both capecitabine HFS (22.3% vs 39.5%, p=0.02) and sorafenib-induced HFSR (54.9% vs 71.4%, p<0.00001). Pyridoxine at higher doses showed a trend towards benefit in preventing all grade HFS (69.6% vs 74.1%, p=0.23).

Conclusions: Urea cream and celecoxib are both effective in preventing HFS/HFSR in patients receiving systemic cancer treatment. Particularly, celecoxib is more effective in preventing all-grade capecitabine-induced HFS, while urea cream shows more benefit in preventing moderate to severe sorafenib-induced HFSR. Studies investigating optimal dosing for celecoxib and urea cream are recommended. There is inadequate evidence to make recommendations regarding pyridoxine.

Keywords: Cancer; Celecoxib; Hand-foot syndrome; Meta-analysis; Pyridoxine; Urea cream.

PubMed Disclaimer

References

    1. Yap Y, Kwok L, Syn N et al (2017) Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine–induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 3(11):1538–1545. https://doi.org/10.1001/jamaoncol.2017.1269 - DOI - PubMed - PMC
    1. Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15(12):1625–1633. https://doi.org/10.1080/14740338.2016.1238067 - DOI - PubMed
    1. Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8(9):652–661. https://doi.org/10.1111/j.1610-0387.2010.07449.x - DOI - PubMed
    1. Macedo LT, Lima JP, dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22(6):1585–1593. https://doi.org/10.1007/s00520-014-2129-z - DOI - PubMed
    1. Yadav N, Madke B, Kar S, Prasad K (2015) Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome. Indian Dermatol Online J 6(5):366–368. https://doi.org/10.4103/2229-5178.164488 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources